Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00928434 · ClinicalTrials.gov registry record · Phase 3
A Study of Degarelix in Patients With Prostate Cancer
A Phase 3 study, sponsored by Ferring Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 409
- Enrollment target
NCT00928434: Completed Phase 3 study, sponsored by Ferring Pharmaceuticals.
NCT00928434 is a Phase 3 study that has completed, run by Ferring Pharmaceuticals. The registered enrollment target is 409 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (47% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00928434, a Phase 3 study, has completed, sponsored by Ferring Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 409 participants
- Enrollment target
Study Summary
The purpose of this study was to see if giving Degarelix every month for 7 months then stop treatment for 7 months (intermittent therapy) would show a reduction of negative effects of androgen deprivation therapy by increasing the quality of life while keeping prostate specific antigen (PSA) levels suppressed.
Primary Outcome
Percentage of patients with serum PSA levels ≤4.0 ng/mL at 14 month was presented.
Interventions
- DRUG Degarelix
- DRUG Leuprolide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 409 participants |
| Start Date | 2009-05 |
| Est. Completion | 2012-08 |
| Phase | Phase 3 |
What the finished NCT00928434 record still lists
NCT00928434 is an interventional study that assigns participants to a tested intervention. The registered 409 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (47% lower).
The record links to 0 conditions, and to 2 interventions - of which Degarelix is the first listed.
NCT00928434 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00928434 about?
NCT00928434 is a clinical study titled "A Study of Degarelix in Patients With Prostate Cancer". The purpose of this study was to see if giving Degarelix every month for 7 months then stop treatment for 7 months (intermittent therapy) would show a reduction of negative effects of androgen deprivation therapy by increasing the quality of life while keeping prostate specific antigen (PSA) levels ...
What is the current status of trial NCT00928434?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 409 participants. The study started on 2009-05. Estimated completion is 2012-08.
What interventions are being tested in trial NCT00928434?
The interventions under investigation include: Degarelix (DRUG), Leuprolide (DRUG).
Who is sponsoring clinical trial NCT00928434?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00928434's enrollment target sits among peer trials
409 911th of 2000 higher than 1,090 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06717334 · 409 participants
A Study of Lung Cancer Screening in People With Unexplained Weight Loss
- NCT02043691 · 410 participants · NA
Evaluation of the Cook Custom Aortic Endograft, the Zenith t-Branch Endovascular Graft, and Surgeon-Modified Endograft in Treating Aortic Pathologies
- NCT03042975 · 410 participants
Imaging Genetics of Laryngeal Dystonia
- NCT05730036 · 410 participants · Phase 3
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia